ad
The Economy

Don’t Assume Financial Advisers Have To Act In Your Best Interests

Posted on 01 March, 2012 | 68 Comments »

The flaws in Canada’s financial adviser system
Barrie Mckenna
OTTAWA— From Saturday’s Globe and Mail
Published Friday, Feb. 17, 2012 6:42PM EST
Last updated Tuesday, Feb. 28, 2012 7:22PM EST
http://www.theglobeandmail.com/globe-investor/the-flaws-in-canadas-financial-adviser-system/article2342799/page3/
In the investing industry, the line between what’s best for the client and what’s good for the adviser is easily blurred.
Advisers want their clients to enjoy high returns, but they [...]

DIY Investing, Insurance

How to protect your retirement funds from creditor claims

Posted on 01 March, 2012 | 77 Comments »

Jeff buckstein
Globe and Mail Update
Published Saturday, Feb. 25, 2012 6:00AM EST
Last updated Tuesday, Feb. 28, 2012 8:24AM EST
Canadians who own registered retirement savings plans recognize the critical importance of building and maintaining value within their RRSPs. But comparatively few think about the need to protect their RRSP against potential creditors, or understand the degree to [...]

Bond Bubble

Why Bonds Are Risky

Posted on 01 March, 2012 | 71 Comments »

The Catch-22 these days is that traditionally lower-risk vehicles may present higher risk in the long run.

DIY Investing, Mutual Funds

High Fund Fees Gobble Up Meagre Returns

Posted on 01 March, 2012 | 75 Comments »

Don’t be the ignorant investor who lets his mutual fund companies make out better than he does.

Insurance

Think Twice About Purchasing Mortgage Life Insurance

Posted on 01 March, 2012 | 67 Comments »

Mortgage life insurance is marketed by the banks as a flexible, low-cost way to protect one of your largest financial obligations. However, you are much better off buying life insurance directly from the insurer. Mortgage life insurance is likely to cost you twice as much as regular life insurance.

The Economy

2011 YEAR IN REVIEW

Posted on 21 December, 2011 | 70 Comments »

It’s that time of the year again when we look back at how our Dec 31, 2010 BNN predictions fared.

2011 was a year marked by uncertainty and volatility, to say the least. With only a few more days to go, 2011 thus far has given investors a rough ride with many feeling bruised and battered. The swings were sharp while the down days dominated the headlines.

Bank Reform, Mutual Funds

Conflicts of Interest In The Canadian Investment Industry – An Insider’s View

Posted on 13 March, 2011 | 65 Comments »


One would think that the collapse of worldwide markets would have provided a wake-up call to governments and investors across the country. And yet, as a Portfolio Manager for private wealth individuals in Canada, I come across many intelligent and sophisticated individuals who have little if any clue as to their all-in management fees with their current adviser. Truth be told, one often needs a forensic scientist to discover how much their investment adviser really earns from managing your money.

M&A

Kindred Acquires Rehab (KND, RHB)

Posted on 17 February, 2011 | 75 Comments »

Under the deal, RehabCare stockholders will receive $26 in cash and 0.471 Kindred shares for each of their shares. Kindred plans to issue about 12 million shares in connection with the transaction. The deal also includes the assumption of about $400 million in debt.

M&A

Nelson Peltz Makes $55-$60 Run At Family Dollar

Posted on 17 February, 2011 | 53 Comments »

Nelson Peltz disclosed he’s offering to buy discount retailer Family Dollar Stores for $55 to $60 a share in cash.
Peltz said last year that he believed Family Dollar’s shares were undervalued, and he said he would discuss with the company ways to improve operating performance.
Family Dollar shares ended the regular trading session at $43.96 a [...]

M&A

Sanofi Acquires Genzyme ($20B Deal)

Posted on 17 February, 2011 | 74 Comments »

Sanofi is paying $74 a share, or $20.1 billion, plus a contingent value right, or CVR—a pledge of additional payment of up to $14 a share if Genzyme meets certain sales and manufacturing targets. Genzyme shareholders will get extra money if Lemtrada, Genzyme’s experimental treatment for multiple sclerosis, makes it to market and achieves certain sales. Shareholders will receive additional money if Genzyme restores manufacturing to certain levels at the plant that has experienced problems.

ad